Elanco Animal Health (NYSE:ELAN) Given New $18.00 Price Target at Stifel Nicolaus

Elanco Animal Health (NYSE:ELAN) had its price objective cut by Stifel Nicolaus from $20.00 to $18.00 in a research report report published on Tuesday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also recently issued reports on the stock. UBS Group initiated coverage on shares of Elanco Animal Health in a report on Monday, December 9th. They issued a “buy” rating and a $18.00 target price for the company. Leerink Partners assumed coverage on Elanco Animal Health in a research note on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective for the company. Leerink Partnrs upgraded Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Finally, Barclays boosted their price objective on shares of Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Elanco Animal Health has an average rating of “Hold” and an average target price of $16.43.

Elanco Animal Health Stock Down 0.9 %

Shares of Elanco Animal Health stock opened at $11.81 on Tuesday. Elanco Animal Health has a one year low of $11.40 and a one year high of $18.80. The company has a market cap of $5.84 billion, a P/E ratio of 29.53, a PEG ratio of 2.03 and a beta of 1.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The firm has a fifty day moving average of $12.73 and a two-hundred day moving average of $13.57.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.12 by $0.01. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the firm earned $0.18 earnings per share. The firm’s revenue was down 3.6% compared to the same quarter last year. On average, analysts forecast that Elanco Animal Health will post 0.92 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its holdings in shares of Elanco Animal Health by 76.6% during the third quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company’s stock worth $147,747,000 after purchasing an additional 4,361,799 shares during the last quarter. State Street Corp lifted its position in Elanco Animal Health by 2.6% during the third quarter. State Street Corp now owns 9,912,693 shares of the company’s stock worth $145,617,000 after buying an additional 255,084 shares during the period. Magnetar Financial LLC boosted its stake in Elanco Animal Health by 61.2% in the 2nd quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock worth $120,298,000 after buying an additional 3,164,350 shares during the last quarter. Geode Capital Management LLC grew its holdings in Elanco Animal Health by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 7,868,675 shares of the company’s stock valued at $115,623,000 after buying an additional 65,303 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Elanco Animal Health by 6.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 6,385,467 shares of the company’s stock valued at $93,803,000 after acquiring an additional 394,921 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.